Benoît Verjans has a PhD degree in biochemistry and an MBA from the University of Brussels. He has made a post-doctoral program at the University of Cambridge (UK). He worked at UCB Pharma in International Marketing, at McKinsey&Co as consultant mainly in pharma sector (marketing, supply chain and licensing projects) and as CEO of 4AZA Bioscience, a start-up from the University of Leuven developing new immuno-modulating drugs. He is currently Scientific Advisor at Aseptic Technologies and CEO of Arlenda, a company specialized in pharmaceutical statistics. Benoît is on the Editorial Board of Pharmaceutical Technology Europe and member of ISPE and PDA.